Emer­gent’s newest an­thrax vac­cine is now FDA-ap­proved

Emer­gent BioSo­lu­tions said its an­thrax vac­cine re­ceived full FDA ap­proval, though the com­pa­ny has pro­vid­ed dos­es of the vac­cine to the US gov­ern­ment for al­most four years un­der pre-emer­gency use au­tho­riza­tion.

Emer­gent an­nounced the news on Thurs­day, say­ing the vac­cine is now brand­ed as Cyfendus and is in­di­cat­ed for post-ex­po­sure pro­phy­lax­is af­ter sus­pect­ed or con­firmed ex­po­sure to the bac­te­ria that caus­es an­thrax, Bacil­lus an­thracis. The two-dose vac­cine is ap­proved in adults 18 to 65 years old and is giv­en in com­bi­na­tion with what Emer­gent called “rec­om­mend­ed an­tibac­te­r­i­al drugs.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER